期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌的BRAF基因突变及其临床意义 被引量：8

Mutation of the BRAF Genes in Non-small Cell Lung Cancer
下载PDF
导出
摘要 BRAF基因是一个驱动基因,可能是靶向治疗非小细胞肺癌的一个靶点。本文就BRAF基因的结构、表达、信号通路调节及研究热点、与肿瘤发生的关系尤其是与非小细胞肺癌的靶向治疗关系加以阐述。 BRAF mutations have been found to be a driver mutation and maybe a therapy target in patients with non-small cell lung cancer.This article reviews the current understanding of BRAF gene,its structure,expression,the signal pathway,as well as its relationship with cancer especially the targeted therapies for non-small cell lung cancer.
作者 黄志敏 吴一龙
机构地区 广东省肺癌研究所
出处 《中国肺癌杂志》 CAS 北大核心 2012年第3期183-186,共4页 Chinese Journal of Lung Cancer
关键词 BF突变 肺肿瘤 靶向治疗 BRAF mutation Lung neoplasms Targeted therapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Ikawa S, Fukui M, Ueyama Y, et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol, 1988, 8(6): 2651-2654.
  • 2Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF- ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116(6): 855-867.
  • 3Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res, 2007, 67(10): 4933-4939.
  • 4Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations in BRAE NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol, 2006, 126(1): 154-160.
  • 5Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomark- ers. J Pathol, 2011, 223 (2): 219-229.
  • 6Xu X, Q uiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res, 2003, 63(15): 4561-4567.
  • 7Kotoula V, Sozopoulos E, Litsiou H, et al. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer, 2009, 16(2):565-572.
  • 8Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892): 949-954.
  • 9Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol, 2011, 29(15): 2046-2051.
  • 10Rosenberg DW, Yang S, Pleau DC, et al. Mutations in BRAF and KRAS differ- entially distinguish serrated versus non-serrated hyperplastic aberrant crypt loci in humans. Cancer Res, 2007, 67(8): 3551-3554.

同被引文献213

  • 1余宗阳,欧阳学农,杜建,季天海,李捷.非小细胞肺癌中胰岛素样生长因子-1受体的表达[J].福州总医院学报,2006,13(4):202-204. 被引量：1
  • 2李琦,赵亚力,郝好杰,李向红.中国肺癌患者EGFR基因的突变研究[J].中华肿瘤杂志,2007,29(4):270-273. 被引量：18
  • 3Piperdi B, Merla A, Perez-Soler R. Targeting angiogenesis in squamous nonsmall cell lung cancer. Drugs, 2014, 74(4): 403-413.
  • 4Mitsudomi T, Morita S, Yatabe Y, ei al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).J Clin Oncol, 2012, 30 (Suppl). Abstr 7521.
  • 5Mok TS, Wu YL, Yu cj, et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.J Clin Oncol, 2012, 30(Supp!): Abstr 7520.
  • 6Mu XL, Li LY, Zhang XT, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with nonsmall cell lung cancer. Clin Cancer Res, 2005, 1l(12): 4289-4294.
  • 7Lai Y, Zhang Z, LiJ, et al. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. IntJ Mol Sci, 2013, 14(12): 24549-24559.
  • 8Hata A, Katakami N, Yoshioka H, et al. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?J Thorac Oncol, 2013, 8( 1): 89-95.
  • 9Shukuya T, Takahashi T, Kaira R, et al. Efficacy of gefitinib for nonadeancareinoma non-small cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci, zou, 102(5): 1032-1037.
  • 10Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res, 2008, 68( 17): 69l3-6921.

引证文献8

二级引证文献39

中国肺癌杂志
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部